A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo

Journal of Infectious Diseases

Volumn 202, Issue 2, 2010, Pages 234-241

  Moscona, Anne ^a,b   Porotto, Matteo ^a,b   Palmer, Samantha ^a,b   Tai, Caroline ^c   Aschenbrenner, Lori ^c   Triana Baltzer, Gallen ^c   Li, Qi Xiang ^c   Wurtman, David ^c   Niewiesk, Stefan ^d   Fang, Fang ^c  

^a Departments of Pediatrics   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NexBio Inc   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DAS 181; HYBRID PROTEIN; SIALIC ACID; SIALIDASE; UNCLASSIFIED DRUG; AMPHIREGULIN; CELL SURFACE RECEPTOR; DAS181; GLYCOPROTEIN; P PROTEIN, HUMAN PARAINFLUENZA VIRUS 2; PHOSPHOPROTEIN; SIALIC ACID RECEPTOR; SIGNAL PEPTIDE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COTTON RAT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LECTIN BINDING; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PLAQUE FORMING CELL; PRIORITY JOURNAL; RAT; RESPIRATORY EPITHELIUM; VIRUS GENE; VIRUS STRAIN; ANIMAL; CELL LINE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PARAMYXOVIRUS INFECTION; SIGMODONTINAE; TRACHEA; VIROLOGY; VIRUS CULTURE;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE DEPLETION; NEURAMINIDASE; PARAMYXOVIRIDAE INFECTIONS; PHOSPHOPROTEINS; PLAQUE ASSAY; RATS; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SIGMODONTINAE; TRACHEA; VIRAL PROTEINS;

EID: 77954573573     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653621     Document Type: Article

References (39)

1. Loughlin GM, Moscona A. The cell biology of acute childhood respiratory disease: therapeutic implications. Pediatr Clin North Am 2006; 53:929-959.
2. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917-1928.
3. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:1141-1148.
4. Madhi SA, Cutland C, Zhu Y, et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 2006; 24:2432-2439.
5. Sato M, Wright PF. Current status of vaccines for parainfluenza virus infections. Pediatr Infect Dis J 2008; 27:S123-S125.
6. Amonsen M, Smith DF, Cummings RD, Air GM. Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin. J Virol 2007; 81:8341-8345.
7. Suzuki T, Portner A, Scroggs RA, et al. Receptor specificities of human respiroviruses. J Virol 2001; 75:4604-4613.
8. Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. Evolving complexities of influenza virus and its receptors. Trends Microbiol 2008; 16:149-157.
9. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005; 79:1113-1124.
10. Villar E, Barroso IM. Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj J 2006; 23:5-17.
11. Porotto M, Fornabaio M, Greengard O, Murrell MT, Kellogg GE, Moscona A. Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site. J Virol 2006; 80:1204-1213.
12. Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 2005; 115:1688-1698.
13. Moscona A, Peluso RW. Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutininneuraminidase in membrane fusion. J Virol 1991; 65:2773-2777.
14. Moscona A, Peluso RW. Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion. J Virol 1992; 66:6280-6287.
15. Moscona A, Peluso RW. Analysis of human parainfluenza virus 3 receptor binding variants: evidence for the use of a specific sialic acidcontaining receptor. Microb Pathog 1996; 20:179-184.
16. Ah-Tye C, Schwartz S, Huberman K, Carlin E, Moscona A. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3. Microb Pathog 1999; 27:329-336.
17. Palermo L, Porotto M, Yokoyama C, et al. Human parainfluenza virus infection of the airway epithelium: the viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. J Virol 2009; 83:6900-6908.
18. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-1479.
19. Moscona A, Peluso RW. Relative affinity of the human parainfluenza virus 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity. J Virol 1993; 67:6463-6468.
20. Triana-Baltzer GB, Babizki M, Chan MC, et al. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother 2009; 65:275-284.
21. Levin Perlman S, Jordan M, Brossmer R, Greengard O, Moscona A. The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3. Virology 1999; 265:57-65.
22. Murrell M, Porotto M, Weber T, Greengard O, Moscona A. Mutations in human parainfluenza virus type 3 HN causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (zanamivir). J Virol 2003; 77:309-317.
23. Nicholls JM, Aschenbrenner LM, Paulson JC, et al. Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J Antimicrob Chemother 2008; 62:426-428; author reply, 428-429.
24. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002; 76:5654-5666.
25. Porter D, Prince G, Hemming V, Porter H. Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rat: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia. J Virol 1991; 65:103-111.
26. Prince GA, Ottolini MG, Moscona A. Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo. J Virol 2001; 75:12446-12451.
27. DeLaMora P, Moscona A. A daring treatment and a successful outcome: the need for targeted therapies for pediatric respiratory viruses. Pediatr Transplant 2007; 11:121-123.
28. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-1759.
29. Groothuis J, Simoes E, Levin M, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants ind young children. N Engl J Med 1993; 329:1524-1530.
30. Schauer R. Chemistry, metabolism, and biological functions of sialic acids. Adv Carbohydr Chem Biochem 1982; 40:131-234.
31. Markwell M, Moss J, Hom B, Fishman P, Svennerholm L. Expression of gangliosides as receptors at the cell surface controls infection of NCTC 2071 cells by Sendai virus. Virology 1986; 155:356-364.
32. Holmgren J, Svennerholm L, Elwing H, Fredman P, Strannegard O. Sendai virus receptor: proposed recognition structure based on binding to plastic-adsorbed gangliosides. Proc Natl Acad Sci U S A 1980; 77: 1947-1950.
33. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 2004; 101:4620-4624.
34. Belser JA, Blixt O, Chen LM, et al. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci U S A 2008; 105:7558-7563.
35. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196:1493-1499.
36. Moscona A. Medical management of influenza infection. Annu RevMed 2008; 59:397-413.
37. Moscona A. Neuraminidase inhibitors for influenza. N Engl JMed 2005; 353:1363-1373.
38. Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A. The anti-influenza virus agent 4-GU-DANA (Zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J Virol 2000; 74:11108-11114.
39. Roth JP, Li JK, Smee DF, Morrey JD, Barnard DL. A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays. Antiviral Res 2009; 82:12-21.